Key result
Between 2003 and 2019, multiple sclerosis prevalence in Alberta increased from 259 to 310 per 100,000 population, while incidence decreased from 21.2 to 12.7 per 100,000 population.
Why the study?
Estimating multiple sclerosis prevalence and incidence, along with assessing DMT and healthcare resource utilisation over time, is critical to understanding disease burden and therapeutic impacts on the healthcare system.
How has the prevalence, incidence, and healthcare utilization of multiple sclerosis changed over time in Alberta, Canada?
Cohort
How has the prevalence, incidence, and healthcare utilization of multiple sclerosis changed over time in Alberta, Canada?
In Alberta, Canada, MS prevalence and outpatient healthcare utilization have increased over time, while incidence and acute care visits have decreased, reflecting evolving disease burden and therapy use.
Answers are grounded in this paper and cite their sources.
Trends in Alberta MS burden and DMT use may guide local planning; leaves open generalizability and causal links to outcomes.
BACKGROUND: Estimating multiple sclerosis (MS) prevalence and incidence, and assessing the utilisation of disease-modifying therapies (DMTs) and healthcare resources over time is critical to understanding the evolution of disease burden and impacts of therapies upon the healthcare system. METHODS: A retrospective population-based study was used to determine MS prevalence and incidence (2003-2019), and describe utilisation of DMTs (2009-2019) and healthcare resources (1998-2019) among people living with MS (pwMS) using administrative data in Alberta. RESULTS: Prevalence increased from 259 (95% confidence interval [CI]: 253-265) to 310 (95% CI: 304, 315) cases per 100,000 population, and incidence decreased from 21.2 (95% CI: 19.6-22.8) to 12.7 (95% CI: 11.7-13.8) cases per 100,000 population. The proportion of pwMS who received ≥1 DMT dispensation increased (24% to 31% annually); use of older platform injection therapies decreased, and newer oral-based, induction, and highly-effective therapies increased. The proportion of pwMS who had at least one MS-related physician, ambulatory, or tertiary clinic visits increased, and emergency department visits and hospitalizations decreased. CONCLUSIONS: Alberta has one of the highest rates of MS globally. The proportion of pwMS who received DMTs and had outpatient visits increased, while acute care visits decreased over time. The landscape of MS care appears to be rapidly evolving in response to changes in disease burden and new highly-effective therapies.
No takes yet. Share an insight, caveat, or question.
Balcom et al. (2024) conducted a cohort in Multiple sclerosis. Time (calendar year) was evaluated on MS prevalence and incidence. Between 2003 and 2019, multiple sclerosis prevalence in Alberta increased from 259 to 310 per 100,000 population, while incidence decreased from 21.2 to 12.7 per 100,000 population.
Synapse has enriched 10 related papers. Consider them for comparative context: